Now showing items 1-10 of 26
Alemtuzumab depletion failure can occur in multiple sclerosis.
Alemtuzumab is a lymphocyte-depleting antibody and one of the most effective treatments for relapsing multiple sclerosis. However, it also causes loss of immune-tolerance leading to secondary autoimmunity and marked anti-drug ...
e-Health and multiple sclerosis: An update.
e-Health (or digital healthcare) is becoming increasingly relevant in multiple sclerosis (MS) clinical management. We aim to review and discuss current status and future perspective of e-health in people with multiple ...
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
Background: A considerable number of people with multiple sclerosis (pwMS) live in low- and middle-income countries (LMIC), where lack of resource adversely affects access to effective disease-modifying treatment. Objective: ...
Cladribine: mechanisms and mysteries in multiple sclerosis.
OBJECTIVES: The aims of this manuscript were to review the evidence for the efficacy and safety of cladribine in multiple sclerosis (MS) and to review the molecular and cellular mechanisms by which cladribine acts as a ...
Neuromyelitis optica spectrum disorder presenting as rhomboencephalitis.
Rhomboencephalitis, at least in its acute phase, is often a severely disabling syndrome, and can be life threatening. A range of underlying conditions can lead to this clinical syndrome. Rapid diagnosis to initiate treatment ...